InflaRx Statistics
Total Valuation
InflaRx has a market cap or net worth of $61.62 million. The enterprise value is $44.28 million.
Important Dates
The last earnings date was Thursday, March 19, 2026, before market open.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InflaRx has 67.75 million shares outstanding. The number of shares has increased by 14.20% in one year.
| Current Share Class | 67.75M |
| Shares Outstanding | 67.75M |
| Shares Change (YoY) | +14.20% |
| Shares Change (QoQ) | +3.76% |
| Owned by Insiders (%) | 6.38% |
| Owned by Institutions (%) | 16.93% |
| Float | 55.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,801.38 |
| Forward PS | 68.59 |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,285.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.13 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,229.89 |
Financial Efficiency
Return on equity (ROE) is -88.63% and return on invested capital (ROIC) is -57.63%.
| Return on Equity (ROE) | -88.63% |
| Return on Assets (ROA) | -45.97% |
| Return on Invested Capital (ROIC) | -57.63% |
| Return on Capital Employed (ROCE) | -114.27% |
| Weighted Average Cost of Capital (WACC) | 12.51% |
| Revenue Per Employee | $465 |
| Profits Per Employee | -$724,049 |
| Employee Count | 74 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, InflaRx has paid $14,421 in taxes.
| Income Tax | 14,421 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.83% in the last 52 weeks. The beta is 1.53, so InflaRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -24.83% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 47.70 |
| Average Volume (20 Days) | 261,350 |
Short Selling Information
The latest short interest is 2.67 million, so 4.21% of the outstanding shares have been sold short.
| Short Interest | 2.67M |
| Short Previous Month | 2.79M |
| Short % of Shares Out | 4.21% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.66 |
Income Statement
In the last 12 months, InflaRx had revenue of $34,438 and -$53.58 million in losses. Loss per share was -$0.80.
| Revenue | 34,438 |
| Gross Profit | -8.50M |
| Operating Income | -56.66M |
| Pretax Income | -53.57M |
| Net Income | -53.58M |
| EBITDA | -56.17M |
| EBIT | -56.66M |
| Loss Per Share | -$0.80 |
Full Income StatementBalance Sheet
The company has $18.81 million in cash and $1.05 million in debt, with a net cash position of $17.76 million or $0.26 per share.
| Cash & Cash Equivalents | 18.81M |
| Total Debt | 1.05M |
| Net Cash | 17.76M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 48.79M |
| Book Value Per Share | 0.69 |
| Working Capital | 47.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.46 million and capital expenditures -$135,839, giving a free cash flow of -$41.04 million.
| Operating Cash Flow | -41.46M |
| Capital Expenditures | -135,839 |
| Free Cash Flow | -41.04M |
| FCF Per Share | -$0.61 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -164,534.71% |
| Pretax Margin | -155,541.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
InflaRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.20% |
| Shareholder Yield | -14.20% |
| Earnings Yield | -86.37% |
| FCF Yield | -66.16% |
Analyst Forecast
The average price target for InflaRx is $8.50, which is 834.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 834.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 159.53% |
| EPS Growth Forecast (5Y) | -18.52% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
